article · Malaria Journal
Malaria remains a major global health threat, responsible for an estimated 247 million infections and over 600,000 deaths across 85 countries in 2021, primarily affecting tropical and subtropical areas. A significant advance in combating the disease is the World Health Organisation endorsement of the R21/Matrix-M malaria vaccine, developed through a partnership between the University of Oxford and Novavax. In Phase 2 clinical trials, the vaccine achieved 77 percent efficacy. The intervention is formulated to be low-dose, cost-effective, and accessible, and has secured approval for administration to children under three years of age. An examination of this vaccine considers its development trajectory, its potential role in accelerating worldwide eradication initiatives, and the accompanying operational challenges and opportunities involved in its deployment.
Malaria continues to claim hundreds of thousands of lives every year, particularly among young children in vulnerable regions. A newly endorsed vaccine demonstrating high efficacy provides a critical, cost-effective preventative measure that could significantly strengthen international public health efforts aimed at eradicating the disease.
The vaccine represents an applied, near-market preventative product already approved for use in children under three years old. Developed for broad accessibility and low manufacturing costs, it is positioned for public health programmes, international health agencies, and governments seeking scalable interventions against malaria across endemic territories.
AI-generated from the published abstract. Always read the original work before citing.
Abstract Malaria affects millions of lives annually, particularly in tropical and subtropical regions. Despite being largely preventable, 2021 witnessed 247 million infections and over 600,000 deaths across 85 countries. In the ongoing battle against malaria, a promising development has emerged with the endorsement by the World Health Organization (WHO) of the R21/Matrix-M ™ Malaria Vaccine. Developed through a collaboration between the University of Oxford and Novavax, this vaccine has demonstrated remarkable efficacy, reaching 77% effectiveness in Phase 2 clinical trials. It is designed to be low-dose, cost-effective, and accessible, with approval for use in children under three years old. This perspective paper critically examines the R21/Matrix-M malaria vaccine, its development, potential impact on global malaria eradication efforts, and the challenges and opportunities it presents.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12936-024-04846-w
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
